LILRB is a type I transmembrane glycoprotein belonging to the leukocyte immunoglobulin-like receptor (LILR) family, also known as the CD85, ILT, or LIR family. It is an immunosuppressive receptor. Its structure consists of an extracellular, transmembrane, and intracellular region: the extracellular region contains four immunoglobulin (Ig)-like domains responsible for ligand binding; the intracellular region contains the immunoreceptor tyrosine inhibitory motif (ITIM), a key region for transmitting inhibitory signals. This family contains five members (LILRB1-LILRB5).
LILRB binds to ligands such as MHC-l, ApoE, and Angptls, inducing ITIM tyrosine phosphorylation, thereby recruiting SHP-1/SHP-2 and SHIP phosphatases to dephosphorylate downstream kinases (Src, Syk, ZAP70, PI3K, etc.), ultimately inhibiting the activation, proliferation, and cytotoxicity of immune cells (such as T cells, NK cells, and macrophages), and promoting tumor immune escape. LILRB targets possess a unique mechanism of action, offering novel strategies for overcoming tumor immunotherapy challenges.
LILRBs are highly expressed in various solid tumors (such as lung cancer, breast cancer, and liver cancer) and hematological malignancies (such as acute myeloid leukemia and multiple myeloma), and are associated with tumor progression, immune escape, and poor prognosis. Meanwhile, members such as LILRB4 are abnormally expressed in autoimmune diseases such as systemic lupus erythematosus and Kawasaki disease, participating in immune tolerance and inflammation regulation. Monoclonal antibodies, CAR-T cells, and ADCs have entered clinical trials, and combining them with PD-1 inhibitors is becoming an important direction.
Anti-CD85a/LILRB3 Antibody (7C5) 是一种靶向 LILRB3/ILT5/CD85a 的人源单克隆抗体,可用于炎症和免疫疾病的研究,推荐同型对照为人 IgG1 kappa,即同型对照 (MS-E04981)。
Anti-LILRB1 Antibody 是一种靶向 LILRB1/CD85j/ILT2 的单克隆抗体,可用于 ELISA、FACS 和功能实验,其同型对照可参考 Human IgG1 kappa, Isotype Control (MS-E04981)。
Anti-LILRB3 Antibody 是一种靶向 LILRB3/ILT5/CD85a 的单克隆抗体,可用于 ELISA、FACS 和功能实验,其同型对照可参考 Human IgG1 kappa, Isotype Control (MS-E04981)。
BND-35 是一种靶向 LILRB4/ILT3/CD85k 的人类单克隆抗体 (mAb),可阻断 ILT3 与 APOE 和纤连蛋白的相互作用,增强各种髓系细胞的促炎活性,并逆转 ILT3 介导的不同抑制性髓系细胞对 T 细胞的免疫抑制,同时在 hILT3 转基因小鼠肿瘤模型中具有抗肿瘤活性。
ES009 是一种高亲和力的 LILRB2 拮抗剂,对 hLILRB2-huANGPTL3 和 hLILRB2-huANGPTL4 的 IC50 分别为 14.07 nM 和 18.61 nM,它通过特异性阻断 LILRB2 与 MHC I 类及非 MHC 配体的相互作用来有效抑制受体激活,同时能重编程抗炎髓样细胞并促使其向促炎表型转化、逆转巨噬细胞介导的 T 细胞抑制作用,在与抗 PD-1 阻断疗法联用时还可协同增强 T 细胞活化,因此可用于晚期实体瘤及卵巢癌的相关研究。
IO-108 是一种人源 IgG4 单克隆抗体,作为 LILRB2 竞争性抑制剂(KD = 1.97 nM),可通过竞争性阻断 LILRB2 与 HLA-G、MHC-I、ANGPTL2、SEMA4A 等配体的结合,重编程肿瘤相关髓系细胞,促使抑制型髓系细胞转化为促炎表型,从而恢复 T 细胞与 NK 细胞的杀伤活性,并能抑制 LILRB2 转基因小鼠模型中的肿瘤生长,因此可用于实体瘤的研究。
IO-202 是一种高亲和力的 LILRB4/ILT3 抑制剂及髓系检查点抑制剂,通过阻断 APOE 结合与 LILRB4 激活来逆转 T 细胞抑制并增强其细胞毒性,同时利用 ADCC 和 ADCP 机制清除高表达 LILRB4 的白血病母细胞,并可促进树突状细胞成熟与抗原呈递、重塑肿瘤相关巨噬细胞表型并减少髓系来源抑制性细胞,从而可广泛应用于复发/难治性急性髓系白血病 (AML)、慢性粒单核细胞白血病 (MML) 及实体瘤的相关研究。
Rolistobart 是一种人源化免疫球蛋白 G4-kappa 抗 LILRB4/CD85k 单克隆抗体,同时也是一种免疫刺激剂和抗肿瘤药。
Zamristobart 是一种具有免疫刺激和抗肿瘤活性的抗 LILRB1(白细胞免疫球蛋白样受体 B1)IgG4κ 型人源化抗体,推荐的同型对照为 Human IgG4 (S228P) kappa, Isotype Control (MS-E39019)。
Polzastobart (JTX-8064) 是一种人源化 IgG4 单克隆拮抗抗体,可选择性结合 LILRB2 并阻止其与配体、经典和非经典 MHC I 分子结合,通过阻断 LILRB2 结合 HLA-A/B 和/或 HLA-G(癌细胞免疫耐受标记)的能力来增强巨噬细胞中促炎细胞因子的产生,是一种巨噬细胞免疫检查点抑制剂。